According to the International Forum for the Study of Itch (IFSI), chronic pruritus can be classified into three categories. The etiological classification of pruritus on primarily non-lesional (IFSI II) skin can be challenging, particularly as many patients with internal medicine conditions suffer from accompanying pruritic symptoms. Practical guidance for a structured approach and a current overview of pathophysiological insights as well as topical and systemic therapeutic options are provided by the recently updated European guideline by interdisciplinary pruritus experts, which contains numerous evidence-based recommendations.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
- Bezafibrate
- biliary tract diseases
- Bylvay
- chronic pruritus
- Difelikefalin
- European guideline
- evidence-based recommendations
- gabapentin
- IFSI
- IFSI II
- internal medicine conditions
- International Forum for the Study of Itch
- Kidneys
- Liver
- Montelukast
- Nalbuphin
- Naltrexone
- Odevixibat
- pruritus experts
- pruritus on primarily non-lesional
- Sertraline
You May Also Like
- Chronic Pruritus in Renal, Hepatic, and Biliary Tract Diseases
Pooled Expertise for Targeted Evaluation and Treatment
- Advanced Thyroid Cancer
Molecular Mechanisms and New Therapeutic Approaches
- Epidermolysis bullosa
Promoting Wound Healing with Gene Therapies and Birch Bark Extract
- From Risk Identification to Anti-Inflammatory Intervention
Inflammation as a Treatment Goal in Its Own Right
- Psoriasis Research: What's in the Pipeline?
Highly selective oral TYK inhibitors in Phase III
- Cardiometabolism
Retatrutid and the TRIUMPH Program: The Triple Agonist on the Horizon
- Pediatric Retinoblastoma
The Tumor Microenvironment and Modern Eye-Sparing Therapies
- Adherence and management in asthma and COPD